!"
#,
("
#
" $%
( () " # % #! & &" " )
# * % * !
# &
# '
(" %
'
% " * !
% % " '
* " +
'
!"#$%"#" &' "#(
!
) #* '
Porcentaje de respondedores
50 43
40
30 23
20
16
10
10
5 2
1
0
0
<84
<86
<88
<90
<92
<94
<96
<98
Ellsburg y cols. J Perinatal 2004; 24: 36 - 40
!"#$%"#" &' "#$
#"+ , "!
,& '
Porcentaje de respondedores
40 33
30
27 22
20
11
10 5 1
0
>84
0
>86
1
>88
>90
>92
>94
>96
>98
Ellsburg y cols. J Perinatal 2004; 24: 36 - 40
-
.!
" % "" #" 5
" , %
& " %
"#!" "#
-.$--/ 0 1-$-2/ (" % # * +
*
-.$--/3 #" 6 " , 7 &, 4 "
(" 4 " "# #
&
" 4" - "
# %
, ( %
" 6 " + ) "
'
!" #!$% ! " %()
#
%/
"#
. +
!"## ! ,"0 "#
/0
1203
% %4#5
6"#!#$7(
-
) &/ /1 /0 ;<
Neonatos, %
7
4
* 1 8
&
3/<
.2;
9
=1
1 /
:1
%"
4$
#
& "1% 2
"! ' 3!
!1"!
! '
1.00
Proporci贸n sobrevivientes
Ventilaci贸n oscilatoria alta frecuencia 0.75
Ventilaci贸n convencional
0.50
0.25 P=0.80 0.00
0
50
100
150
Dias 3/'1 /1
/0
1201 3
%4("7%%$4
",* "4 &
Pacientes exit贸samente extubados (%)
100
3! "4 # 2
1#
Ventilaci贸n oscilatoria alta frecuencia Ventilaci贸n SIMV
80
60
40
20
0
P=0.006
0
10
20
30
/ 1
40 50 Edad (D铆as) /0
60
1201 3
70
80
*/0%4(
90
/ # "74%$7!
"
!.'## *
> ?/
3!
%5 ""! "#"#
@>*
> ?/
#!A
0.1
1
"+ #1"! '
#
*
10
0 . ## ,
; 11 B C0 0?.
D
@> $,*
##7
/* /
##( ###
E 0 0 ##7
@> $
E C ##)
/* /
'/;
/,* /
###
/ /
/
@> $,* / /
*
1
3/'1 /1
&/0 01
/0
;3
=
*/0 7)
=
! $
!!
%
-
F
&
G
+
# 6 ) ""# 65 " * 8 3 2/ ) 99/ *
+ , & " * 4"
-
* +
+
*
% 0 4#
)
" - "
>
(" 8
" %
% #
, ( ")
)
#
" #" :
Van Marter y Cols. Pediatrics 2000; 105: 1194-1201 Henderson y Cols. Cocrhane Database Sist. Rev 2000;2: CD000104
2
10 9 8 7 Líquidos (mL • Kg-1h-1) 6 5 4 Entrada 3 Salida 2 1 0
, / ;HI;/ / 1
6
Lactante varón “A” 29 semanas de gestación PN= 1 200 g
8 16 24 32 40 48 56 64 72 80 88 96 104 112
Edad (horas)
1.0 0.9 0.8 0.7 0.6 0.5 FIO2 0.4 0.3 0.2 0.1 0
6
Peso al nacer (g)
< 70 70 - 90 91 - 125 – 1 – 1 – 1 – 1 ml . Kg d ml . Kg d ml . Kg–1 d–1 (%) (%) (%)
;<< $ ---
=9
=>
=<<< @ =2--
==
=;
=;
=1
>
.
<
;.=
.19
=12
=;<< @ =>;< A
##
2 9=-
22?
> 125 ml . Kg–1 d–1 (%)
2.?
Gersony WM Cols. J Pediatr 102:895, 1983
RESTRICTED VERSUS LIBERAL WATER INTAKE FOR PREVENTING MORBIDITY AND MORTALITY IN PRETERM S INFANTS
3
$
B#
"
%7
"# C2 3* + " " ** #4" " , , % " : # , # " , " 8
" " 5 " "% * " * 6 4 " % "" % * # <
.<$1<
DE D
!
21$>9 +"
3
F =;< % GD '
Bell E, Acarregui M. Cochrane Database Syst Rev 2001; (3):CD000503
L
8
8
8 " !K '
J% "
)
" " # *
9=
0
# =.
<9 0
E
4
4
5# #
9<
<9
0
" *
B" %
%
#
( 0D0
=
(# 0D0
2
# 8
%
%
% #
I 2>/
*
$ 9</
I 9=/
$ 9=/
I H;/
</
"#
% " ) # * # % "
% " %
" (
H<
<9
0
# % # H "#
I =9/
&
12 /1
"
"
$ =2:;
/0
01
#
,
/ ' ;
##(" #!$
7 100 90 80
StcO2
70 60 50 40 30 20 10 0 C
P
100
200
400
Salbutamol (Âľg) Denjean A y cols J Pediatr 1992; 120: 974 - 979
8
#
Disminución en Rrs (%)
60
Inhaador Dosis Medida
55
Nebulizador Jet Nebulizador Ultrasó Ultrasónico
50
45
40
40
38 32
30
30
30 20
18
20
18 15
10 3
0
15
30
60
120
Duración efecto terapeútico aerosolterapia (minutos) Fok J y cols Arch Dis Chil Fetal Neonatal Ed 1998; 79 – F100 – F104
.'"## !%
( #
3!
%+
% M*
* +
8,
8 ! " + 3
# &
1
2
" * "% ,"- " '
() " # % # D8" %: 1J 1 /0 3 /0 ; ? = @/0 /0 =
" " ##
%
" #(4$#(# ## 4 " %($ 4 ##! 4 " 4!$ !
0
#
*
# %
"
"
#
%
4 "
%
4
*
& /1 +
% ( #%
/0" / ' 1 B /
# %
"
# %
"
"
#
"
< /0 3
? ##4
% 4" (
) ( $()
9 :
4
Distensibilidad dinรกmica (ml/cmH2O/kg)
> / ;
) 7 4 0
</
K 4
7
)
L '
/0
0 1
$
9 / ;
9 /
' /1
&
*/0
(
/
=
;
<
9
:
!
RPT (cmH2O/L/sec)
0
</
!
> / ; K !
!
4
7
'
)
/0 3
##
("
$
)
% Cambio en resistencia pulmonar
!
* 4
&
%
$ $
)
%
7 ;=/ 5; 16
<'
'
'0 >
0
/1
0
##( (( 5 6"% >$%!>
=
=: 9:
" " , 5 " # "% # "G "% # %* N5 J % O H: J *# + )# *% # *", " 3 " #" 7 3 9$2 %,DP,D "
#
3
=$H%,DP,D & /1 + <'
( # <9 " " #,"" - "& =9
"
92 5 " =9Q 92 5 "
/0" / ' 1 < B / /0 3 ' ' 0 > 0 /1 0 ' /0 3
? % ) ( ##4 4" ( $() ##( (( 5 6"% >$%!> ## (" $ )
#"!#&'% %%!.,
*#% >
PFT Number 1,6
I
II
III
V
IV Placebo DiurĂŠtico
Cdyn (mL/cmH2O/kg)
1,4 1,2 1 0,8 0,6 0,4 0,2 0
0
10
20
30
40
50
60
Semanas desde inicio estudio Kao y cols. J Peditr 1994; 124 (5): 772 - 81
"##"!
1?
> " *#% >
PFT Number 100
I
II
III
IV
V DiurĂŠtico Placebo
Raw (cmH2O/L/sec)
90 80 70 60 50 40 30
0
10
20
30
40
50
60
Semanas desde inicio estudio Kao y cols. J Peditr 1994; 124 (5): 772 - 81
! 3! * ' , !
*#% >
PFT Number 1
I
II
III
IV
V
Vmax FRC (TGV/sec)
Placebo DiurĂŠtico
0,8
0,6
0,4
0,2
0
0
10
20
30
40
50
60
Semanas desde inicio estudio Kao y cols. J Peditr 1994; 124 (5): 772 - 81
=
5 4 ) " % % * + * 7 * ( , # " # * 3" ," ( *
& /1 +
/0" / ' 1 B / & 12 /1 /0
% # " " % "4 " - " * 5 " "
< ? % ) ( /0 3 ##4 4" ( $() 01 / ' ; ##(" #!$
"
") "
"%
"
"% *& + # " +
/1
#
#" " *
% * N
@ 1
" "
/0 / ' 1
( ",%B "
" ( #% < /0 3
" " #
"4
"O ? #))
%# " !$
* 9-/6 * %
"
& =DH:2 & =<<< ," 3
* ! % " % @ 1
/1
(# #
3
(# # 6 3=D9
3 ;</ '
/0 / ' 1
< /0 3
? #))
%# " !$
-
# % % #
M6G + ,
") M
+ & 7# 5*" K 6 6G
+M M
"% ,* " 6 %A B J pediat 28 : 1999;135:526-* " " % 6 ) # * Schmitd 6( #1999;135:526, " " % " ", ") " #"M
1 0 0*
? , /0 3 ;< 0? 1 1 D' /0 ' '0 >
0
= 493
'0 @ 0 %7" 4($! 01 1 /0 % % 5 6 /1 0 )%" >%#$4%
%/ "%
';
&
! 5 "!
/0
! # %"
1203
7 %!4"
$
%5
! *"# * *' "&
';
&
/0
' 5 "! 1#
1203
7 %!4"
$
.!
%
""
# 2< = *%+ ",, "" # (# (
@ 1
",*
5 4
%: ! *
%
+ " "
(" %
'
" - "&
) # 3 .$=9% " D%#9<% " D%# ) # 3 9<$2< % " D%#
/1
/0 / ' 1 ;< 0? 1 1
< D'
01
? 1
/0
%# % % 5 6
#, " 8 % % B
4
5 " "%
( #%
#% D %
"
%
4
)
( *% % " # %
" *
# *
"%
# *
# "%
(# # % (
# *, *
5 % ,+ (
"# *,
#" *
" "# #
" %
"
(
5 # J
)" ,
) 5
16 Esteroides Control
5;0 N.= N.26
14 12 10 8 6 4 2
0
2
4
6
8
10
12
14
Edad (dĂas) Fok C Y Cols. Arch Dis Child Fetal Neonatal ed 1999; 80:F203-208
60 Esteroides Control
5.= N0 N 6
50
40
30
20
10
0
2
4
6
8
10
12
14
Edad (dĂas) >/.
/0
'
'0 >
0
/1
0
### ) " >
%$
)
/
"%
" 5
& ) 4 %
%
# +% ""
*
8
0
4" " ==:-/ ! -;/
@ 0 0
"
!
# % "% 32:.$=-:9/'
4" " 9:1-! -;/
# " B# 3=:-.$2:9>'
,
,#
@+ ' 1. 1C / ; 1
# 3
/' 1 < ;3 = ' /0 1203
%
" 3
" "# 3 ==D= ? 4
%# % 7)" %!7$%#7 %! " % 4$ % %
@ @A A 2 2
Estudio Estudio
Esteroide Esteroide Inhalado Inhalado
Esteroide Esteroide Sisté émico Sist Sistémico
Riesgo Riesgo Relativo Relativo (Fijo) (Fijo) 95% 95% CI CI
Peso Peso (%) (%)
Riesgo Riesgo Relativo Relativo (Fijo) (Fijo)
n/N n/N
n/N n/N
Hallidey Hallidey 2001 2001
49/143 49/143
32/135 32/135
100.0 100.0
1.45 1.45 [0.99 [0.99 -- 2.11] 2.11]
Total Total (95% (95% CI) CI)
49/143 49/143
32 32 /135 /135
100.0 100.0
1,45 1,45 [0.99 [0.99 -- 2.11] 2.11]
95% 95% CI CI
Test =0.00 df heterogenicidad quare Test para para heterogenicidad: heterogenicidad:: chis chis quare=0.00 quare=0.00 df == 00 Test Test para para efeco efeco general general == 1.91 1.91 p=0.06 p=0.06
1
2
1
Favorece Favorece inhalado inhalado 55 553 3 55
5
10
Favorece Favorece Sistmico Sistmico 5" 5"
" 4 6 9': "" " 4 60 0# #% % ! ! 9': 9<<2 9<<2
;
<
2
Estudio Estudio
Esteroide Esteroide Promedio Promedio (80) (80) Esteroide Esteroide Mediana Mediana (80) (80) Inhal Sisté émico N Sist Inhal (N) (N) Sistémico N
WMD WMD 95% 95%
Peso Peso (%) (%)
diferencia diferencia
CI CI
95% 95% CI CI
Gronieck Gronieck 1999 1999
77
21.00 21.00 (7.08) (7.08)
00
15.20 15.20 (1.20) (1.20)
48.5 48.5
5.80 5.80 (0,56 (0,56 -- 11.04) 11.04)
Hallidey Hallidey 2001 2001
143 143
20.00 20.00 (20.70) (20.70)
135 135
17.90 17.90 (22.50) (22.50)
51.5 51.5
2.10 -2,99 -- 7,19) ((-2,99 2.10 (7,19)
Total Total (95% (95% CI) CI)
150 150
100.0 100.0
3,89 3,89 (0,24 (0,24 -- 7,55) 7,55)
144 144
Test =0.98 df -11 heterogenicidad quare 0.32 Test para para heterogenicidad: heterogenicidad:: chis chis quare=0.98 quare=0.98 df == 1p 1p == 0.320.32-11 Test Test para para efec efec general general == 2.09 2.09 p=0.04 p=0.04 -10
-5
Favorece Favorece inhalado inhalado 55 553 3 55
0
5
10
Favorece émco Favorece sist sistémco 5" 5"
" 4 6 9': "" " 4 60 0# #% % ! ! 9': 9<<2 9<<2
B
" ," ! '
8 %
# H. #
! 'D F -.
>
"
=2
RH
%
)# * % % " 8 ! 'D
# # " & * # 91 ! 'D
=:<;! <:-9 =:9='
<:.9! <:;= <:>;'D-
<:1.! <:><:-2'D=2
<:1<! <:.> <:-.'D==
<:>=! <:22 =:=;'D
<:.9! <:2> <:19'D2
<:.H! <:;= <:>1'D2
<:>=! <:9=:>;'
=:<.! <:>H =:;.'
<:>.! <:;1 =:<<
<:>H! <:;1 <:-H'
<:;2! <:H9 <:-9'D=< #5 6"%% $%%)
C -
INCIDENCIA DE DISCAPACIDAD (%)
O
4 /
= =
)
/
44 !)
7
4
%#A
A
) 7 , =/ I; /1 5 O( 6
, =/ /1 /0 5 O(46
'
/0
1203
4
%! " % 4$ 4$ % %
@A 2
Estudio Estudio
Tratamiento Tratamiento n/N n/N
Control Control n/N n/N
Riesgo Riesgo Relativo Relativo (Fijo) (Fijo) 95% 95% CI CI
Peso Peso (%) (%)
Riesgo Riesgo Relativo Relativo (Fijo) (Fijo) 95% 95% CI CI
Cole Cole 1999a 1999a
19/123 19/123
23/130 23/130
69.0 69.0
0.67 ,52] ,52] 0.67 [0.50 [0.50 -- â&#x20AC; â&#x20AC; ,52]
fok fok 1999 1999
1/27 1/27
3/26 3/26
9.4 9.4
0.32 0.32 [0.04 [0.04 -- 2.89] 2.89]
Jan Jan gaasd gaasd 1998 1998
4/30 4/30
5/30 5/30
15.4 15.4
0.60 2.69] 0.60 [0.24 [0.24 --2.69]
Mera Mera 1999 1999
0/12 0/12
0/11 0/11
0.0 0.0
No No estimable estimable
Yong Yong 1999 1999
0/20 0/20
2/20 2/20
6.2 6.2
3.00 3.00 [0.09 [0.09 -- 13.12 13.12 ]]
Total Total (95% (95% CI) CI)
30/20 30/20
33/217 33/217
100.0 100.0
0.94 0.94 [0.60 [0.60 -- 1.40] 1.40]
Test =2.73 df heterogenicidad square Test para para heterogenicidad: heterogenicidad:: chi chi square=2.73 square=2.73 df == 33 p=4348 p=4348 Test Test para para efecto efecto general general == 1.20 1.20 p=0.2 p=0.2 1
2
1
5
Favorece Favorece Tratado Tratado 55 553 3 55
10
Favorece Favorece Control Control 5" 5"
" 4 6 "" " 4 60 0# #% %
! 9'6 ! 9'69<<2 9<<2
& & +
&
; 0
0.30
0.20
/< < 0
Placebo 0.10 Beclometasona 0.00 0
7
14
21
28
DĂas de Vida /0
/0
1203
### %4 "
!$
2 " * =:<>! -;/
&, # 91 3<:1;$=:H2'
" * &, # H. <:->! -;/ 3<:>1$=:9<' * <:>1! -;/
" 3<:.9':
+% 3 =D=<
* % # & <:=9 ! -;/ 3<:<<H$<:2H' +
/0
/' 1
<
%
?
*
<
%# #5 6"%% $%%)
2
% #7 " ) * +
" # *"
,
)
"
""
(
4
+%
#"
- "
# 8
"
#
+
/0
/' 1
<
?
#5 6"%% $%%) %#
CONCLUSION: La suplementaci贸n con vitamina A est谩 asociada con una reducci贸n en la mortalidad y las necesidades de 02 al mes y a las 36 sems postconcepcional en menores de 1000 gramos.
* +
*
, DOSIFICACION RECOMENDADA: ;<<< " " 9<<< " " +" F9<% D # '
"2 "2
0 /E & , ' ; /' 1 & 1 0 ; 3 1 ; , /2 9 9 1
% %
" - "
! )#
< ? 546" )5 6" $7 ? %576" !$ %
!
&
# ) " J
( &
&
( * , " %
* " #+,
* " #
&
% )
"$ &
# 5 %
G
"4 4 - "
> "
=<<< ," 3
03 9:1$H:; DP,D 0 3 .$=9 DP,D
4"
=<<< ," 3
9;$;<
D
:
Greer F. Ped Clin North Am 2001(4) : 101-125 Premer D, Georgieff M Pedr in Rev 2002: 23(6):225-231
") ) , ( 8"
*
#
) # 8
# & "
%B
"
(
% 40
" # %
% 4 &
)
," 4
" # %
*
" +
"(" #%
0 % 8 4
"
& &
)
%
" # "" ", #" % "
" * 5 " # &: " 6,#
" # (" % 6# (=
<96 "